Search
for
Sort by
Research 871–900 of 1000+
- 1640: Polymorphisms in the 5α-Reductase Type 2 Gene and Response to Finasteride Treatment in BPH
- Market Analysis of 5α-Reductase Inhibitor
- 9th ANNUAL MARCH 5. 8. 2003. ORLANDO. F.L LIVE SURGERY WORKSHOP Sponsored by The International Socity of Hair Restoration Surgery
- New Synthesis of Methyl 3β-Hydroxy-5-androstene-17β-carboxylate
- Genetic alteration of cyclic adenosine 3',5'-monophosphate-dependent protein kinase subunit expression affects calcium currents and beta-endorphin release in AtT-20 clonal pituitary cells.
- 10.1063/5.0132123.1
- Comparative study between the efficacy and safety of topical sildenafil citrate solution and topical minoxidil 5%in the treatment of female pattern hair loss .
- Comparison between “5% minoxidil plus 2% flutamide” solution vs. “5% minoxidil” solution in the treatment of androgenetic alopecia
- Comparative Study of The Effect of Topical Minoxidil 5% Versus Combined Fractional CO2 Laser and Topical Minoxidil 5% in Treatment of Male Androgenetic Alopecia
- Effectiveness of Topical Minoxidil (5%) Plus Topical Finasteride (0.1%) Fixed-Dose Combination Versus Topical Minoxidil (5%) Plus Oral Finasteride (1 Mg/Day) in Grade II-IV Androgenetic Alopecia: A Randomized, Double Blind Clinical Trial
- Crystal structure of Steroid 5-alpha-reductase 2 in complex with Finasteride
- Effect of iontophoresis with growth factor cocktail containing fibroblast growth factor 5-short applied to the scalp in patients with androgenetic alopecia – A split study
- Therapeutic effects of growth factor cocktail (CellcurinTM) containing FGF5s (fibroblast growth factor 5 short) and NMN (nicotinamide mononucleotide) in patients with androgenetic alopecia: A split study
- FC 2-2 : Therapeutic Effects of Growth Factor Cocktail (CellcurinTM) containing FGF5s (fibroblast growth factor 5 short) and NMN (nicotinamide mononucleotide) applied on the scalp in the patients with androgenetic alopecia: a split study
- A randomised trial of 5% minoxidil versus combination of 5% minoxidil and oral spironolactone in treatment of female pattern hair loss
- Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss
- Dual effects of 5α-reductase inhibitor dutasteride on androgenetic alopecia and acne vulgaris
- Systemic cyproterone acetate and 5% minoxidil topical in the treatment of female pattern hair loss
- Faculty Opinions recommendation of Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
- Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
- Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
- Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata
- Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
- Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up
- The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assessment of finasteride and dutasteride
- Constitutive Internalization of the Leucine-rich G Protein-coupled Receptor-5 (LGR5) to the Trans-Golgi Network
- Chronic telogen effluvium: A study of 5 patients over 7 years
- Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial
- Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism
- Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride